Lv1
20 积分 2026-08-06 加入
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
1个月前
已完结
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape
1个月前
已完结
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
2个月前
已完结
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
2个月前
已完结
皖公网安备34019202002308
